Read this perspectives piece from Brett Wilson, head of Monitoring Excellence at Bristol-Myers Squibb (BMS), and leader of the TransCelerate RBM Initiative.
TransCelerate BioPharma addresses key issues in clinical development and recently, six members companies have decided to extend the concept to the preclinical realm by establishing the subsidiary, BioCelerate.
Our news subsidiary BioCelerate launched with an aim to improve efficiencies in preclinical research. The first initiative, Toxicology Data Sharing, which will enable access to a broader cross-company set of toxicology data.
Check out our press release and video detailing our newly launched Shared Investigator Platform, a technology that will revolutionize communications between sites and sponsors
Read this recent Q&A with our Lead of the QMS Initiative.
The Clinical Data Interchange Standards Consortium (CDISC), the Critical Path Institute (C-Path), and TransCelerate BioPharma Inc. announce that Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia have been published for use and accessible on the CDISC website.
A group of nine authors involved with TransCelerate BioPharma Inc. were honored with a Global Inspire Award at DIA’s 2015 Annual Meeting.
The recipients of the Author(s) of the Year Award published “Defining a Central Monitoring Capability: Sharing the Experience of TransCelerate BioPharma’s Approach, Part 1,” in DIA’s official, scientific, peer-reviewed journal, Therapeutic Innovation & Regulatory Science. This award recognizes their published article as the most widely read article of the DIA publications in 2014.
TransCelerate BioPharma Inc. announced the establishment of two new global initiatives which will accelerate and enhance clinical trials. Both initiatives – Placebo / Standard of Care Data Sharing and Electronic Labels for Clinical Trials (eLabels), aim to create solutions that will have a direct impact on patients, sponsors and investigative sites.